After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Preliminary results from Exelixis' (EXEL) CaboNivo drug trial indicated issues among nine of 24 patients participating in the study.
Cramer says Fiserv is a winner and to pull the trigger on EPR Properties.
Focus on finding stocks of high-quality companies at good prices, Cramer advises.
Here's a look at two stocks that are trending higher and two that are ripe for short-selling.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.